Navigation Links
International ENDORSE Study Shows That the Majority of Hospitalized,Patients Surveyed are at Risk for VTE and Many do not Receive,Recommended VTE prophylaxis

efinition of patients at risk of VTE and prophylaxis recommendations provided by the of Chest Physicians (ACCP) evidence-based consensus guidelines (3). The study included two categories of hospitalized patients: patients in medical wards 40 years of age or older, and patients in surgical wards, 18 years or older.

Doctor Fred Anderson, Director of the Center for Outcomes Research at the University of Massachusetts Medical School who conducted the study commented "ENDORSE is the first study to provide a global view of VTE risk and prophylaxis practices throughout the world. With more than 60,000 patients studied in more than 30 countries, the scope of ENDORSE is unprecedented. In view of the quality of the data collected and a common method to assess patients at risk for VTE and prophylaxis used, this study gives us a unique picture both globally and locally about the extent of the hospitalized patient population at risk for VTE and how these patients are managed."

ENDORSE demonstrates the high prevalence of patients at risk for VTE: 52% of hospitalized patients surveyed were at risk for VTE, corresponding to 64% of surgical patients and 42% of medical patients. The prevalence of patients at risk was consistent across the countries surveyed, demonstrating the importance of VTE risk on a global scale.

Importantly, when considering the use of recommended prophylaxis in hospitals, only 50% of hospitalized patients at risk for VTE received a method of prophylaxis recommended by the ACCP, corresponding to 59% of surgical and 40% of medical patients at risk for VTE. The use of recommended prophylaxis varied across countries; however, it was globally sub-optimal and even more so in medical than surgical patients, as the majority of medical patients at risk for VTE (60%) did not receive recommended prophylaxis.

As highlighted by Doctor Victor Tapson, Co-chair of the ENDORSE Steering Committee: "ENDORSE clearly shows that VTE is a critical safety i
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
6. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
8. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
11. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
Post Your Comments:
(Date:3/3/2015)... 2015 Research and Markets ( ... "Telemedicine and Mobile Healthcare Solutions, Services, and ... report to their offering. ... terms that pertain to the use of telecommunications ... clinical/non-clinical healthcare services. They form the ecosystem that ...
(Date:3/3/2015)... RADNOR, Pa. , March 3, 2015 /PRNewswire/ ... of laboratory products, services and solutions, announced today ... England Biolabs®, Inc. (NEB®). This agreement allows VWR ... renowned technical support in the U.S. and Puerto ... to NEB,s products through VWR,s e-business platform, sales ...
(Date:3/3/2015)... BETHESDA, Md. , March 3, 2015 /PRNewswire/-- ViaCyte, Inc., ... cell-derived islet replacement therapy for the treatment of diabetes ... Eugene Brandon , Director of Strategic Relations and ... summit showcases the latest in type 1 diabetes management ... are as follows: , , , Title:   ...
Breaking Medicine Technology:Global Telemedicine and Mobile Healthcare Solutions, Services, and Devices: Market Analysis and Forecasts 2015 - 2020 2Global Telemedicine and Mobile Healthcare Solutions, Services, and Devices: Market Analysis and Forecasts 2015 - 2020 3VWR Announces Expansion of Distribution Agreement with New England Biolabs 2ViaCyte to Present at JDRF TypeOneNation Research Summit 2
(Date:3/4/2015)... Professionals with disabilities are eager to ... companies, according to a new Think Beyond the Label ... 235 professionals with disabilities , respondents also say they ... including ones that are geared to people with disabilities, ... ,     Online job search tools are used by ...
(Date:3/4/2015)... 04, 2015 The medical device landscape ... management forgot – or ignored or didn't know – ... market based on physician input before proceeding to design ... specifically, founders – become so enamored of an innovative ... Will physicians use the device?” says Dr. Kathryn ...
(Date:3/3/2015)... Anik Singal's Profit Academy - ... marketers has become the talk of the town ... surrounding the course's general release has garnered the ... her to review the program's content and publish ... biggest keys to success with Internet marketing is ...
(Date:3/3/2015)... March 03, 2015 On February 21st, ... the fabulous EcoLuxe Lounge, a day-long event that features ... conscious products and services. Organized by Debbie Durkin and ... film placement producer, the EcoLuxe Lounge saw many notable ... roles on General Hospital, The Flash, Star Trek: Deep ...
(Date:3/3/2015)... March 03, 2015 Findings could lead ... at UC Davis have developed and characterized a molecule ... causing them to self-destruct. This novel mechanism was found ... a usually fatal type of brain cancer – and ... , The article, to be published in the April ...
Breaking Medicine News(10 mins):Health News:Job Seekers with Disabilities Seek Targeted Outreach from Employers and Online Job Search Tools, says New Think Beyond The Label Survey 2Health News:Job Seekers with Disabilities Seek Targeted Outreach from Employers and Online Job Search Tools, says New Think Beyond The Label Survey 3Health News:Want to Succeed in Medical Technology? Don't Innovate in a Vacuum 2Health News:Want to Succeed in Medical Technology? Don't Innovate in a Vacuum 3Health News:Anik Singal's Profit Academy - Review Of New IM Training Program Released 2Health News:Hollywood Star Chase Masterson and Choices Recovery Discuss Substance Abuse and Treatment at 2015 Oscars 2Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 2Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 3Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 4
... could actually be caused as a result of a defect ... after scientists have worked towards identifying important skin cancer genes ... scientists to look at thousands of genes at once, helping ... greater detail. There are over 200 different types of cancer ...
... ketoacidosis (DKA) is a life-threatening condition that frequently ... The critical factors in the treatment of DKA ... skillful fluid and electrolyte adjustment, and the initiation ... fluid volume has been achieved. Continuous low-dosage intravenous ...
... Anderson Cancer Center have found that weight gain or ... of prostrate cancer. ,The report is detailed in ... Research, corroborates findings of an earlier research that had ... Strom, Ph.D., an associate professor in the Department of ...
... Phase II study to 12 months confirm the significant effects ... patients with relapsing multiple sclerosis (MS). ,The data, ... both patient groups taking FTY720 (1.25 mg and 5 mg) ... of more than 50% during the first six months of ...
... chronic illness that requires continuing medical care and ... to reduce the risk of long-term complications//. As ... care practitioners are confronted with an ever-increasing tide ... Undiagnosed chronic kidney disease (CKD) is common in ...
... an ancient myth that coco bean can be used to treat ... limit the development of fluids that cause diarrhea//. ,The use ... 16th century by ancient South American and European cultures. Until now, ... bean or more specifically why it has been used in the ...
Cached Medicine News:Health News:Novartis MS Drug Shows Promising Results 2Health News:Novartis MS Drug Shows Promising Results 3
... simple, effective method for determining color vision ... data which can be applied to many ... set consists of four trays containing a ... that have incremental hue variation on one ...
... D15 test evaluation has a choice ... caps with automatic creation 'horse-shoe' diagrams, ... deficiency analysis, calculation of color confusion ... eye selection (OD, OS, OU) and ...
... Farnsworth D15 test is used ... color defect vs normal. Farnsworth ... which permit the patient to ... Then the box is closed ...
HRR/Amsler book combo with occluding glasses....
Medicine Products: